4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Sell
8
VYGR Quote, Financials, Valuation and Earnings
Last price:
$5.45
Seasonality move
:
25.01%
Day range:
$5.35 - $5.75
52-week range:
$5.19 - $10.66
Dividend yield:
0%
P/E ratio:
8.38x
P/S ratio:
1.86x
P/B ratio:
0.90x
Volume:
615.3K
Avg. volume:
444.1K
1-year change:
-35.2%
Market cap:
$297.7M
Revenue:
$250M
EPS (TTM):
$0.65
Analysts' Opinion
-
Consensus RatingVoyager Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.10, Voyager Therapeutics has an estimated upside of 213.76% from its current price of $5.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $5.45.
Fair Value
-
According to the consensus of 10 analysts, Voyager Therapeutics has 213.76% upside to fair value with a price target of $17.10 per share.
VYGR vs. S&P 500
-
Over the past 5 trading days, Voyager Therapeutics has underperformed the S&P 500 by -6.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Voyager Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Voyager Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Voyager Therapeutics reported revenues of $24.6M.
Earnings Growth
-
Voyager Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Voyager Therapeutics reported earnings per share of -$0.16.
Enterprise value:
-47.7M
EV / Invested capital:
--
Price / LTM sales:
1.86x
EV / EBIT:
-5.25x
EV / Revenue:
-0.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.66x
Price / Operating cash flow:
50.49x
Enterprise value / EBITDA:
-3.37x
Gross Profit (TTM):
--
Return On Assets:
6.54%
Net Income Margin (TTM):
15.8%
Return On Equity:
9.12%
Return On Invested Capital:
9.12%
Operating Margin:
-55.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $70.5M | $158.4M | $163.8M | $4.6M | $24.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$20.6M | $43.4M | $9.1M | -$29.5M | -$13.8M | |
| EBITDA | -$13.7M | $47.3M | $14.1M | -$28.6M | -$12.6M | |
| Diluted EPS | -$0.46 | $1.23 | $0.65 | -$0.59 | -$0.16 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $216.3M | $126.2M | $146.9M | $261.9M | $373.4M | |
| Total Assets | $269.8M | $184.8M | $182.5M | $294.7M | $426M | |
| Current Liabilities | $42.1M | $26.7M | $73.2M | $61.7M | $44.2M | |
| Total Liabilities | $103.5M | $97.4M | $102.7M | $118.4M | $95.7M | |
| Total Equity | $166.2M | $87.4M | $79.8M | $176.2M | $330.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.9M | $89.4M | -$24.5M | -$21.1M | -$28M | |
| Cash From Investing | -$26.9M | -$154.4M | -$40.8M | -$158.3M | $64.4M | |
| Cash From Financing | $1.1M | $33.5M | $113.9M | $331K | $14K | |
| Free Cash Flow | $9M | $86M | -$28.7M | -$21.8M | -$28.2M | |
VYGR
Sector
Market Cap
$297.7M
$47.5M
Price % of 52-Week High
51.13%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-35.35%
-0.74%
1-Year Price Total Return
-35.2%
-34.04%
Beta (5-Year)
0.929
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.80
200-day SMA
Sell
Level
$7.36
Bollinger Bands (100)
Sell
Level
5.8 - 6.92
Chaikin Money Flow
Buy
Level
34.7M
20-day SMA
Sell
Level
$5.92
Relative Strength Index (RSI14)
Sell
Level
38.07
ADX Line
Sell
Level
26.25
Williams %R
Buy
Level
-89.1304
50-day SMA
Sell
Level
$6.19
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
226.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.6286)
Buy
CA Score
(Annual)
Level (2.4336)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-5.0979)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Stock Forecast FAQ
In the current month, VYGR has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VYGR average analyst price target in the past 3 months is $17.10.
-
Where Will Voyager Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Voyager Therapeutics share price will rise to $17.10 per share over the next 12 months.
-
What Do Analysts Say About Voyager Therapeutics?
Analysts are divided on their view about Voyager Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Voyager Therapeutics is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Voyager Therapeutics's Price Target?
The price target for Voyager Therapeutics over the next 1-year time period is forecast to be $17.10 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VYGR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Voyager Therapeutics is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VYGR?
You can purchase shares of Voyager Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Voyager Therapeutics shares.
-
What Is The Voyager Therapeutics Share Price Today?
Voyager Therapeutics was last trading at $5.45 per share. This represents the most recent stock quote for Voyager Therapeutics. Yesterday, Voyager Therapeutics closed at $5.45 per share.
-
How To Buy Voyager Therapeutics Stock Online?
In order to purchase Voyager Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
